Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
Nyu Ny Nichd Crs
479
mi
from 43215
New York, NY
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
Nyu Ny Nichd Crs
479
mi
from 43215
New York, NY
Click here to add this to my saved trials
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
Harlem Hosp. Ctr. NY NICHD CRS
481
mi
from 43215
New York, NY
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
Harlem Hosp. Ctr. NY NICHD CRS
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
SUNY Upstate Med. Univ., Dept. of Peds.
414
mi
from 43215
Syracuse, NY
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
SUNY Upstate Med. Univ., Dept. of Peds.
414
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
DUMC Ped. CRS
352
mi
from 43215
Durham, NC
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
DUMC Ped. CRS
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
St. Jude/UTHSC CRS
507
mi
from 43215
Memphis, TN
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
St. Jude/UTHSC CRS
507
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
Texas Children's Hosp. CRS
995
mi
from 43215
Houston, TX
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
Texas Children's Hosp. CRS
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
1797
mi
from 43215
San Juan,
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
1797
mi
from 43215
San Juan,
Click here to add this to my saved trials
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated:  10/16/2017
Howard Univ. Washington DC NICHD CRS
mi
from 43215
Washington, D.C.,
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects
Status: Enrolling
Updated: 10/16/2017
Howard Univ. Washington DC NICHD CRS
mi
from 43215
Washington, D.C.,
Click here to add this to my saved trials
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations
Status: Enrolling
Updated:  10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations
Status: Enrolling
Updated: 10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection
Status: Enrolling
Updated:  10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection
Status: Enrolling
Updated: 10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
Status: Enrolling
Updated:  10/17/2017
University of Colorado at Denver
1162
mi
from 43215
Denver, CO
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
Status: Enrolling
Updated: 10/17/2017
University of Colorado at Denver
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy
Status: Enrolling
Updated:  10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy
Status: Enrolling
Updated: 10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy
Status: Enrolling
Updated:  10/18/2017
University of Pittsburgh
164
mi
from 43215
Pittsburgh, PA
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy
Status: Enrolling
Updated: 10/18/2017
University of Pittsburgh
164
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
University of California, Irvine
1958
mi
from 43215
Irvine, CA
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
University of California, Irvine
1958
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
IMMUNOe International Research Centers
1156
mi
from 43215
Centennial, CO
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
IMMUNOe International Research Centers
1156
mi
from 43215
Centennial, CO
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Allergy Associates of the Palm Beaches, PA
924
mi
from 43215
North Palm Beach, FL
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Allergy Associates of the Palm Beaches, PA
924
mi
from 43215
North Palm Beach, FL
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Family Allergy and Asthma Research Institute
188
mi
from 43215
Louisville, KY
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Family Allergy and Asthma Research Institute
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Children's Hospital New Orleans- LSUHSC School of Medicine
799
mi
from 43215
New Orleans, LA
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Children's Hospital New Orleans- LSUHSC School of Medicine
799
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Midwest Immunology Clinical and Infusion Center
637
mi
from 43215
Plymouth, MN
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Midwest Immunology Clinical and Infusion Center
637
mi
from 43215
Plymouth, MN
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Oklahoma Institute of Allergy & Asthma Clinical Research
849
mi
from 43215
Oklahoma City, OK
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Oklahoma Institute of Allergy & Asthma Clinical Research
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Vital Prospects Clinical Research Institute, P.C.
750
mi
from 43215
Tulsa, OK
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Vital Prospects Clinical Research Institute, P.C.
750
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Dallas Allergy Immunology Research
906
mi
from 43215
Dallas, TX
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Dallas Allergy Immunology Research
906
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Allergy, Asthma & Immunology Clinic, P.A.
913
mi
from 43215
Irving, TX
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Allergy, Asthma & Immunology Clinic, P.A.
913
mi
from 43215
Irving, TX
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Rocky Mountain Asthma/Allergy/Immunology
1515
mi
from 43215
Layton, UT
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Rocky Mountain Asthma/Allergy/Immunology
1515
mi
from 43215
Layton, UT
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Emory University
435
mi
from 43215
Atlanta, GA
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Emory University
435
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
SSM Cardinal Glennon Children's Medical Center
396
mi
from 43215
Saint Louis, MO
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
SSM Cardinal Glennon Children's Medical Center
396
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Montefiore Medical Center Division of Allergy/Immunology
486
mi
from 43215
The Bronx, NY
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Montefiore Medical Center Division of Allergy/Immunology
486
mi
from 43215
The Bronx, NY
Click here to add this to my saved trials
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  10/19/2017
Centre Hospitalier Universitaire (CHU) Sainte-Justine
610
mi
from 43215
Montreal,
Phase 2/3 Study of IGSC, 20% in PIDD
A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 10/19/2017
Centre Hospitalier Universitaire (CHU) Sainte-Justine
610
mi
from 43215
Montreal,
Click here to add this to my saved trials
Aspirin and Antiretroviral Therapy in HIV Infected Patients
The Effect of Aspirin and Antiretroviral Therapy on Cardiovascular Risk in HIV Infected Patients: A Pilot Study
Status: Enrolling
Updated:  10/19/2017
Hennepin County Medical Center
623
mi
from 43215
Minneapolis, MN
Aspirin and Antiretroviral Therapy in HIV Infected Patients
The Effect of Aspirin and Antiretroviral Therapy on Cardiovascular Risk in HIV Infected Patients: A Pilot Study
Status: Enrolling
Updated: 10/19/2017
Hennepin County Medical Center
623
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Cardiovascular Prevention for Persons With HIV
Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study
Status: Enrolling
Updated:  10/19/2017
Hennepin County Medical Center
623
mi
from 43215
Minneapolis, MN
Cardiovascular Prevention for Persons With HIV
Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study
Status: Enrolling
Updated: 10/19/2017
Hennepin County Medical Center
623
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications
A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy
Status: Enrolling
Updated:  10/23/2017
Indiana Clinical Research Center
166
mi
from 43215
Indianapolis, IN
Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications
A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy
Status: Enrolling
Updated: 10/23/2017
Indiana Clinical Research Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Disclosure to Family
Maybe, Maybe Not: Deciding to Disclose HIV Status to Family
Status: Enrolling
Updated:  10/24/2017
University of South Florida
822
mi
from 43215
Tampa, FL
Disclosure to Family
Maybe, Maybe Not: Deciding to Disclose HIV Status to Family
Status: Enrolling
Updated: 10/24/2017
University of South Florida
822
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Enhancing PrEP in Community Settings (EPIC)
Enhancing PrEP in Community Settings (EPIC)
Status: Enrolling
Updated:  10/24/2017
Stroger Hospital and the CORE Center
274
mi
from 43215
Chicago, IL
Enhancing PrEP in Community Settings (EPIC)
Enhancing PrEP in Community Settings (EPIC)
Status: Enrolling
Updated: 10/24/2017
Stroger Hospital and the CORE Center
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Repeat Sexually Transmitted Infection (STI) Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk
Repeat STI Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk
Status: Enrolling
Updated:  10/25/2017
University of Wisconsin Milwaukee - Zilber School of Public Health
330
mi
from 43215
Milwaukee, WI
Repeat Sexually Transmitted Infection (STI) Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk
Repeat STI Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk
Status: Enrolling
Updated: 10/25/2017
University of Wisconsin Milwaukee - Zilber School of Public Health
330
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
Brief Alcohol Intervention in HIV+ Women
Status: Enrolling
Updated:  11/2/2017
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
Brief Alcohol Intervention in HIV+ Women
Status: Enrolling
Updated: 11/2/2017
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
966
mi
from 43215
Fort Lauderdale, FL
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
966
mi
from 43215
Fort Lauderdale, FL
Click here to add this to my saved trials
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
797
mi
from 43215
Orlando, FL
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
797
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
864
mi
from 43215
Vero Beach, FL
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
864
mi
from 43215
Vero Beach, FL
Click here to add this to my saved trials
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated:  11/2/2017
GSK Investigational Site
348
mi
from 43215
Charlotte, NC
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Status: Enrolling
Updated: 11/2/2017
GSK Investigational Site
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Risk Assessment of Long-Haul Truck Drivers
Risk Assessment of Long-Haul Truck Drivers
Status: Enrolling
Updated:  11/3/2017
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Risk Assessment of Long-Haul Truck Drivers
Risk Assessment of Long-Haul Truck Drivers
Status: Enrolling
Updated: 11/3/2017
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Alabama Vaccine CRS
493
mi
from 43215
Birmingham, AL
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Alabama Vaccine CRS
493
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Bridge HIV CRS
2109
mi
from 43215
San Francisco, CA
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Bridge HIV CRS
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Hope Clinic of the Emory Vaccine Center CRS
433
mi
from 43215
Decatur, GA
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Hope Clinic of the Emory Vaccine Center CRS
433
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
UIC Project WISH CRS
277
mi
from 43215
Chicago, IL
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
UIC Project WISH CRS
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
641
mi
from 43215
Boston, MA
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
641
mi
from 43215
Boston, MA
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Fenway Health Clinical Research Site CRS
641
mi
from 43215
Boston, MA
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Fenway Health Clinical Research Site CRS
641
mi
from 43215
Boston, MA
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
NY Blood Ctr./Union Square CRS
478
mi
from 43215
New York, NY
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
NY Blood Ctr./Union Square CRS
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Columbia P&S CRS
481
mi
from 43215
New York, NY
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Columbia P&S CRS
481
mi
from 43215
New York, NY
Click here to add this to my saved trials